# US 2011/0218515 A1 · Methods for Treating Acute Myocardial Infarctions and Associated Disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2011/0218515 A1
- Document ID: US20110218515A1
- Status: Published application
- Kind: A1
- Application number: 13/115,697
- Filed: 2011-05-25
- Published: 2011-09-08
- Earliest claimed: 2009-01-26
- Assignees: The Regents of the University of California
- Inventors: Jeff Olgin
- Web page: https://patentgrep.com/patent/US20110218515A1

## CPC

- A61K 31/415: 1,2-Diazoles
- A61K 31/00: Medicinal preparations containing organic active ingredients
- A61K 31/4365: the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
- A61K 31/437: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A61K 31/4418: having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
- A61K 31/4433: containing a six-membered ring with oxygen as a ring hetero atom
- A61K 31/4436: containing a heterocyclic ring having sulfur as a ring hetero atom
- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61K 31/444: containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 31/4965: Non-condensed pyrazines
- A61K 31/50: Pyridazines; Hydrogenated pyridazines
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 31/513: having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K 31/53: having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine (melarsoprol A61K31/555 {; with four nitrogen atoms A61K31/495})
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 31/706: containing six-membered rings with nitrogen as a ring hetero atom
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates to methods of treating patients who have suffered an acute myocardial infarction (AMI) with a therapeutic that has anti-fibrotic effects, for example, pirfenidone and analogs thereof.

## Claims

### Claim 1

A method of treating a patient who has suffered an acute myocardial infarction (AMI) comprising administering to the patient a therapeutically effective dose of pirfenidone or salt thereof, wherein the pirfenidone treatment is initiated at a time period of 1 to 14 days after the patient has suffered the AMI.

### Claim 2 (depends on 1)

The method of claim 1, wherein the pirfenidone treatment is initiated at a time period of 3 to 14 days after the patient has suffered the AMI.

### Claim 3 (depends on 2)

The method of claim 2, wherein the pirfenidone treatment is initiated at a time period of 7 days after the patient has suffered the AMI.

### Claim 4 (depends on 1)

The method of claim 1, wherein the pirfenidone treatment continues up to 6 months.

### Claim 5 (depends on 1)

The method of claim 1, wherein the pirfenidone treatment continues up to 3 months.

### Claim 6 (depends on 1)

The method of claim 1, wherein the pirfenidone treatment reduces ventricular remodeling.

### Claim 7 (depends on 1)

The method of claim 1, wherein the pirfenidone treatment reduces the incidence of one or more of ventricular arrhythmias, congestive heart failure, and sudden cardiac death.

### Claim 8 (depends on 1)

The method of claim 1, wherein the pirfenidone treatment controls or reduces infarct size.

### Claim 9 (depends on 1)

The method of claim 1, wherein the patient has not suffered or does not suffer from chronic myocardial infarction.

### Claim 10 (depends on 2)

The method of claim 2, wherein the therapeutically effective dose of pirfenidone or salt thereof is 1 mg/kg to 60 mg/kg per day.

### Claim 11

A method of reducing the incidence of congestive heart failure in a patient who has suffered an acute myocardial infarction (AMI), comprising administering to the patient a therapeutically effective dose of pirfenidone or salt thereof.

### Claim 12 (depends on 11)

The method of claim 11, wherein the pirfenidone administration is initiated at a time period of 1 to 42 days after the patient has suffered the AMI.

### Claim 13 (depends on 11)

The method of claim 11, wherein the pirfenidone administration is initiated at a time period of 3 to 14 days after the patient has suffered the AMI.

### Claim 14 (depends on 13)

The method of claim 13, wherein the therapeutically effective dose of pirfenidone or salt thereof is 1 mg/kg to 60 mg/kg per day.

### Claim 15 (depends on 12)

The method of claim 12, wherein the patient has not suffered or does not suffer from chronic myocardial infarction.

### Claim 16

A method of controlling or reducing ventricular remodeling in a patient who has suffered an acute myocardial infarction (AMI) comprising administering to the patient a therapeutically effective dose of pirfenidone or salt thereof, wherein the pirfenidone administration is initiated at a time period of 1 to 14 days after the patient has suffered the AMI.

### Claim 17 (depends on 16)

The method of claim 16, wherein the pirfenidone administration is initiated at a time period of 3 to 14 days after the patient has suffered the AMI.

### Claim 18 (depends on 16)

The method of claim 16, wherein the pirfenidone administration is initiated at a time period of 7 days after the patient has suffered the AMI.

### Claim 19 (depends on 18)

The method of claim 18, wherein the therapeutically effective dose of pirfenidone or salt thereof is 1 mg/kg to 60 mg/kg.

### Claim 20 (depends on 16)

The method of claim 16, wherein the patient has not suffered or does not suffer from chronic myocardial infarction.
